Table 7.

Estimated 3-year mean difference in change from baseline on total SPPB score in the three intervention groups compared with the control group (95% CI).

	ω3-PUFA vs. Placebo Mean (n; 95% CI)	Raw p Value (within Sub-Group Intervention vs. Placebo)	Adjusted p Value * (within Sub-Group Intervention vs. Placebo)	ω3-PUFA + Multidomain Intervention vs. Placebo Mean (n; 95% CI)	Raw p Value (within Sub-Group Intervention vs. Placebo)	Adjusted p Value * (within Sub-Group Intervention vs. Placebo)	Multidomain Intervention + Placebo vs. Placebo Mean (n; 95% CI)	Raw p Value (within Sub-Group Intervention vs. Placebo)	Adjusted p Value * (within Sub-Group Intervention vs. Placebo)
Low DHA and EPA in red blood cells †	0.129 (109; −0.411 to 0.670)	0.638	0.638	−0.139 (100; −0.674 to 0.396)	0.610	0.638	0.227 (87; −0.332 to 0.786)	0.425	0.638
Normal DHA and EPA in red blood cells †	−0.110 (285; −0.410 to 0.190	0.472	0.964	0.006 (190; −0.293 to 0.306)	0.964	0.964	−0.021 (304; −0.317 to 0.275)	0.888	0.964
High adherent to the Multidomain intervention (at least 75% of the sessions)	−0.110 (278; −0.382 to 0.161)	0.425	0.447	0.115 (201; −0.182 to 0.413)	0.447	0.447	0.178 (238; −0.109 to 0.466)	0.225	0.447
Low adherent to the Multidomain intervention (less than 75% of the sessions)	−0.284 (102; −0.781 to 0.211)	0.260	0.504	−0.249 (199; −0.583 to 0.085)	0.143	0.431	−0.118 (179; −0.466 to 0.229)	0.504	0.504

BMI, Body Mass Index; MMSE, Mini-Mental State Examination; SPPB, Short Physical Performance Battery. A positive value of change is in favor of the intervention, whereas a negative value is in favor of the placebo. DHA = docosahexaenoic acid. EPA = eicosapentaenoic acid. * Adjusted for multiple comparisons with the Hochberg procedure to account for the fact that three intervention groups were compared with the placebo group in each analysis; † Low concentrations of DHA and EPA were defined by the lowest quartile of DHA plus EPA percentage at baseline in the intention-to-treat population (i.e., 4.83); SD, Standard Deviation.